In this study, we provide evidence that circulating levels of CXCL1, CXCL10 and CXCL13 are distinctly altered in patients with BTC and that serum CXCL13 levels, in particular, represent a promising candidate to predict outcomes following tumor resection. This evidence concerns the gene CXCL13 and neoplasm.